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Abstract 
Previous studies have shown that undenatured type II collagen (UC-II) is effective in the 
treatment of rheumatoid arthritis, and preliminary human and animal trials have shown it to 
be effective in treating osteoarthritis (OA). The present clinical trial evaluated the safety and 
efficacy of UC-II as compared to a combination of glucosamine and chondroitin (G+C) in the 
treatment of OA of the knee. The results indicate that UC-II treatment was more efficacious 
resulting in a significant reduction in all assessments from the baseline at 90 days; whereas, 
this effect was not observed in G+C treatment group. Specifically, although both treatments 
reduced the Western Ontario McMaster Osteoarthritis Index (WOMAC) score, treatment 
with UC-II reduced the WOMAC score by 33% as compared to 14% in G+C treated group 
after 90 days. Similar results were obtained for visual analog scale (VAS) scores. Although 
both the treatments reduced the VAS score, UC-II treatment decreased VAS score by 40% 
after 90 days as compared to 15.4% in G+C treated group. The Lequesne’s functional index 
was used to determine the effect of different treatments on pain during daily activities. 
Treatment with UC-II reduced Lequesne’s functional index score by 20% as compared to 6% 
in G+C treated group at the end of 90-day treatment. Thus, UC-II treated subjects showed 
significant enhancement in daily activities suggesting an improvement in their quality of life. 
Key words: undenatured type II collagen, osteoarthritis, glucosamine, chondroitin, WOMAC, vis-
ual analog scale, Lequesne’s Functional Index 
INTRODUCTION 
Arthritis afflicts approximately 43 million 
Americans or approximately 16.6% of the US popula-
tion. The two most common types of arthritis are os-
teoarthritis (OA) and rheumatoid arthritis (RA). OA 
of the knee and hip is a growing health concern and is 
the most common forms of arthritis (1-3). Pain and 
disease can range from very mild to very severe (3). 
Patients with OA have pain that typically worsens 
with weight bearing, including walking and standing, 
and improves with rest (4). Other symptoms include 
morning stiffness and gelling of the involved joint 
after periods of inactivity. Currently, OA affects Int. J. Med. Sci. 2009, 6 
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nearly 21 million people in the United States, ac-
counting for 25% of visits to primary care physicians, 
and half of all Non-Steroidal Anti-Inflammatory 
Drugs (NSAID) prescriptions. The diverse clinical 
patterns of OA are observed in approximately 10% of 
people older than 60 years thus compromising the 
quality of life of millions of Americans. In addition, 
OA costs the North American economy approxi-
mately $60 billion per year.  
  Current treatment of OA includes exercise, 
heat/cold therapy, joint protection, weight loss, 
physiotherapy/occupational therapy and medica-
tions (3-5). The most common medications include 
acetaminophen and NSAIDs. Although these drugs 
are effective for reducing pain associated with OA, 
they do not reverse the disease. In addition, there are 
considerable side effects associated with the use of 
these drugs. As a result, OA sufferers have turned to 
natural nutraceuticals to ease their pain and discom-
fort. These products are commonly used because they 
are well tolerated and considered safe. Nutraceuticals 
are defined as functional foods, natural products, or 
parts of food that provide medicinal, therapeutic, or 
health benefits, including the prevention or treatment 
of disease. Currently, glucosamine and chondroitin 
are the two most commonly used nutraceuticals in 
humans as well as in animals to alleviate pain associ-
ated with arthritis (6). However, recent randomized 
controlled trials and meta-analysis of these supple-
ments have shown only small-to-moderate sympto-
matic efficacy in human OA (7). An emerging novel 
nutraceutical ingredient known as UC-II has received 
considerable attention in the treatment of OA. UC-II is 
a novel undenatured type II collagen derived from 
chicken sternum cartilage. Previous studies have 
shown that undenatured type II collagen is effective 
in the treatment of RA (8-11), and preliminary human 
(12) and animal (13) trials have shown it to be effective 
in treating OA. Obese-arthritic dogs given 4 mg or 40 
mg daily dose of UC-II for 90 days showed significant 
declines in overall pain, pain during limb manipula-
tion and lameness after physical exertion (14). Greater 
improvement was observed with the 40 mg dose. No 
adverse effects or significant changes in serum chem-
istry were noted. Following UC-II 
withdrawal for a period of 30 days, 
all dogs experienced a relapse of overall pain, exer-
cise-associated lameness and pain upon limb ma-
nipulation. Studies have also shown that small doses 
of orally administered undenatured type II chicken 
collagen inhibit killer T-cell attack (15). The present 
clinical trial evaluated the safety and efficacy of UC-II 
in the treatment of the knee in OA patients. 
Materials and Methods     
Study Design 
  This clinical trial (Human Clinical Trial Ap-
proval #06UOHI) was managed by KGK Synergize 
Inc. (London, ON, Canada). The study was conducted 
at two sites: 1) KGK Synergize Inc., and 2) Corunna 
Medical Research (Corunna, ON, Canada). Figure 1 
illustrates the study design while Table 1 lists the 
procedures and observations at each time point. 
  Briefly, at screening (Visit 1) the consent form 
was discussed, signed and a complete physical ex-
amination was performed. Activity level, diet history, 
medication/supplement use and medical history 
were recorded. The VAS score, the WOMAC Index 
and Lequesne scores were obtained. Urine was col-
lected for a pregnancy test for women of childbearing 
potential. A blood sample was taken for determina-
tion of uric acid, CBC count and differentiation, al-
bumin, total protein, sodium, potassium, chloride, 
BUN, creatinine, ALT, AST, bilirubin, erythrocyte 
sedimentation rate (ESR) and rheumatoid factor. 
Upon review of blood test results, eligible subjects 
were instructed to get an X-ray of the affected knees to 
confirm diagnosis. A total of 52 subjects were re-
cruited using the inclusion and exclusion criteria out-
lined in Table 2. At the first treatment visit (Visit 2), 
selected subjects were randomly assigned to receive 
UC-II (n = 26) or glucosamine HCl plus chondroitin 
sulfate (n = 26, G+C). On each test day (day 0, 30, 60, 
90), subjects were required to come to the clinic for 
clinical assessment. The clinical assessments included 
WOMAC, Lequesne’s functional index and 100-mm 
VAS pain scores. A subject treatment diary was com-
pleted by each patient throughout the study period to 
determine side effects, medication use, and product 
compliance.  
 
 
Figure 1. UC-II clinical study design. 
The study was a two-site, randomized, 
double-blind study conducted in Lon-
don, Ontario and Corunna, Ontario, 
Canada. 
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Table 1. Schedule of observations and procedures 
Procedure Visit  1 
Screening 
Visit 2 
Day 0 
Visit 3 
Day 30 
Visit 4 
Day 60 
Visit 5 
Day 90 
Informed consent  X         
Review inclusion/exclusion  X  X  X  X  X 
Medical history including activity level and diet history  X         
Physical examination  X         
Biometric measurements: 
Weight, height*, heart rate and blood pressure. 
X X  X  X  X 
Urine pregnancy test  X         
Concomitant medications  X  X  X  X  X 
Blood samples: 
Uric acid, CBC count and differentiation, albumin, total 
protein, sodium, potassium, chloride, BUN, creatinine, 
ALT, AST, bilirubin, ESR, rheumatoid factor  
X      X 
WOMAC, VAS and Lequesne scores  X  X  X  X  X 
X-ray X         
Randomization   X       
Blood sample: ALT, AST, bilirubin, albumin. 
 
   X † X †  
Knee flexion, Time to walk 50m, Swelling in the knee joint, 
Time for climbing 10 steps 
 X  X  X  X 
Physician's Global Assessment    X  X  X  X 
Subject's Global Assessment    X  X  X  X 
Investigational Product dispensed    X  X  X   
Subject Treatment Diary dispensed    X  X  X   
Investigational Product returned 
Compliance calculated 
   X  X  X 
Subject Treatment Diary returned      X  X  X 
Adverse Events        X  X  X 
* height was only measured at visit 1 
† If acetaminophen use was greater than 2 g/day for more than 7 days 
 
Table 2. Inclusion and exclusion criteria 
Inclusion Criteria 
Males and females 40-75 years old 
Females of childbearing potential must agree to use a medically approved form of birth control and have a negative urine pregnancy test 
result 
Unilateral or bilateral OA of the knee for greater than 3 months (American College of Rheumatology criteria) confirmed by radiologist's 
report, i.e. X-rays showing osteophytes, joint space narrowing or subchondral bone sclerosis (eburnation) 
Erythrocyte sedimentation rate (ESR) < 40 mm/hr 
Moderate OA as indicated by Lequesne’s functional index score of 4.5-7.5 after 7 day withdrawal of usual medications 
Able to walk 
Availability for duration of study period (3-4 months) 
Subject using other therapies for OA, such as exercise, heat/cold therapy, joint protection and physiotherapy/occupational therapy agrees 
to continue these therapies as normal avoiding changes in frequency or intensity and to record therapies in the study diary 
Subject agrees not to start any new therapies for OA during the course of the study 
Able to give informed consent 
Exclusion Criteria 
History of underlying inflammatory arthropathy; septic arthritis; inflammatory joint disease; gout; pseudogout; Paget's disease; joint frac-
ture; acromegaly; fibromyalgia; Wilson's disease; ochronosis; haemochromatosis; heritable arthritic disorder or collagen gene mutations or 
rheumatoid arthritis 
History of asthma, history of diabetes (Type I or Type II) 
Hyperuricemia (urate, males > 480 umol/L, females > 450 umol/L) 
Expectation of surgery in the next 4 months 
Recent injury in the area affected by OA of the knee, i.e. meniscal tear (past 4 months) 
Cartilage reconstruction procedure in the target knee 
Severe OA as indicated by Lequesne’s functional index score of 8 or greater, after 7 day withdrawal of usual medications 
Intra-articular corticosteroid injections in the target knee within the last 3 months 
Viscous injections in the target knee within the last 6 months 
Hypersensitivity to NSAIDs 
Abnormal liver or kidney function tests (ALT or AST > 2 times the upper limit of normal; elevated creatinine, males > 125 umol/L, females > 
110 umol/L)  Int. J. Med. Sci. 2009, 6 
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Abnormal findings on complete blood count 
History of coagulopathies, history of peptic ulceration and upper GI hemorrhage 
Uncontrolled hypertension 
History of congestive heart failure, history of allergic reaction to chicken and/or eggs 
History of allergic reaction to local anesthetic or to any ingredients in the test product including shellfish  
Hyperkalemia (potassium > 6.2 mmol/L) 
Anticipated problems with product consumption 
History of cancer as well as gastrointestinal, renal, hepatic, cardiovascular, hematological, or neurological disorders 
High alcohol intake (>2 standard drinks per day) 
Pregnant, breastfeeding or planning to become pregnant during the study 
History of psychiatric disorder that may impair the ability of subjects to provide written informed consent 
Use of other natural health products, including glucosamine and chondroitin, one month prior to study and during the study, other than 
multivitamin and mineral supplements containing vitamins and minerals as the sole medicinal ingredients 
Use of concomitant prohibited medication (narcotics, oral NSAIDs, topical NSAIDs) within four weeks of randomization 
Use of acetaminophen or ibuprofen within 7 days of randomization 
Subject is unwilling to stop taking pain medication other than the study medication (for arthritis or other types of pain) or is unwilling to 
stop taking other medications for the treatment of OA 
Any other condition that, in the opinion of the investigator, would adversely affect the subject's ability to complete the study or its measures
 
 
Supplements 
 Each  UC-II  (InterHealth Nutraceuticals, Inc., 
Benicia, CA) capsule contained 20 mg UC-II stan-
dardized to 5 mg of bioactive undenatured type II 
collagen. Subjects in the UC-II group were instructed 
to take two “sugar pills” in the morning to protect 
blinding and two UC-II capsules in the evening ac-
counting for a daily dose of 40 mg UC-II containing 10 
mg of bioactive undenatured type II collagen.  
  Each G+C capsule contains 375 mg of 
glucosamine HCl (USP Grade) and 300 mg of chon-
droitin sulfate (USP Grade). The subjects were in-
structed to take two G+C capsules in the morning and 
two in the evening for a daily dose of 1500 mg gluco-
samine and 1200 mg chondroitin.   
Removal of Patients from Therapy or Assess-
ment 
The criteria for removal of patients from the 
study included: 
Adverse events 
  For any adverse event, patients were examined 
and appropriately managed or the patients would be 
referred to another medical professional for proper 
evaluation and treatment. If medical problems were 
attributed to the trial compounds, then the trial drugs 
were discontinued and the toxicities were reported. 
Personal reasons 
  As stated in the Consent Form, subjects were 
able to withdraw from the study for any reason at any 
time. 
Clinical judgment of physician 
  Subjects were withdrawn from the study 
(without penalty) if, in the opinion of the treating 
physician, it was not in the patient’s best interest to 
continue. For instance, if during the course of the 
study a patient became pregnant, she would be with-
drawn from the study because it was not known how 
the study compounds/medications might affect an 
unborn child. 
Protocol violation 
 Any subject found to have entered this study in 
violation of the protocol or failed to follow the study 
protocol were discontinued from the study at the 
discretion of the Principal Investigator. Subjects were 
withdrawn for protocol non-compliance if they ad-
hered to the dosing schedule less than 75% of the 
time. 
Method of assigning patients to treatment groups 
 Patients were assigned to treatment groups (or-
der of treatments) using computer-generated ran-
domization tables. Patients were not stratified or as-
signed using any other specific method and were not 
randomized after stratification or blocking proce-
dures. 
Selection of doses in the study 
  The justification for the daily dose of 40 mg 
UC-II in capsules (providing 10 mg of undenatured 
collagen II) is based on efficacy demonstrated in ear-
lier studies (8,9). 
Blinding 
    In order to protect blinding, subjects were 
given bottles containing product labeled with “AM” 
or “PM” to distinguish the time in which treatment 
was to be taken. Each bottle contained descriptions of 
all potential products to ensure blinding was pro-
tected. Additionally, each bottle was labeled with a 
randomization number. In the event that an adverse 
effect was considered serious and related to the in-
vestigational product, the blind would be broken for Int. J. Med. Sci. 2009, 6 
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that individual subject.  
  Neither the patient, nor investigator, nor re-
search staff, were aware which test compound the 
subject was assigned. Interim analysis was performed 
in order to write a preliminary report and thus pre-
liminary unblinding occurred by an individual unre-
lated to the study conduct. Personnel related to 
analysis, statistics, and report writing remained 
blinded. 
Prior and concomitant therapy 
  U s e s  o f  m e d i c a t i o n s  s u c h  a s  n a r c o t i c s ,  o r a l  
NSAIDS, topical NSAIDS within four weeks of ran-
domization and during the study, were not allowed.  
Treatment compliance 
  Compliance was assessed by capsule count at 
visits 3, 4, and 5 and review of subject diary.  
Efficacy and Safety Variables 
Efficacy and safety measurements assessed 
Adverse events 
   During the study, subjects recorded adverse 
effects in their subject diary. At each visit, the subjects 
were asked if they experienced problems or difficul-
ties. Any adverse events were documented and re-
corded in the study record and was classified ac-
cording to the description, duration, severity, fre-
quency, and outcome. The investigator assessed the 
adverse events and decided causality. Classifications 
were as per the Coding Symbol Thesaurus of Adverse 
Reaction Terms (COSTART) U.S. Food and Drug 
Administration (16).  
Blood tests 
  Blood samples were taken from all subjects 
during screening (visit 1) and at end of study (visit 5). 
Blood samples (approximately 15 ml) were taken from 
subjects at day 30 and day 60 (visits 3 and 4) for the 
determination of ALT, AST, bilirubin, and albumin if 
the subjects had been taking acetaminophen greater 
than 2 g/day for more than 7 days. All blood samples 
were analyzed by MDS Laboratory Services (London, 
Ontario, Canada). 
Appropriateness of Measurements 
 The efficacy and safety assessments used in this 
study were standard for OA and are widely used and 
recognized as reliable, accurate, and relevant. 
  WOMAC scores were determined, at screening, 
and baseline, as well as at days 30, 60 and 90 as de-
scribed in Bellamy et al (17). Other objectives also 
performed at days 0, 30, 60 and 90 included determi-
nation of Lequesne’s functional index, VAS pain 
scores, knee flexion, time to walk 50 m, time to climb 
10 steps, physician’s and subject’s global assessment. 
The Lequesne’s functional index is described in Le-
quesne et al. (18). 
Statistical Methods 
 Sample size of 25 subjects per group was based 
on the subject number used in Braham et al. (1). To 
compare UC-II with G+C group, a linear contrast was 
included in the analysis of variance. Data missing 
subsequent to 30 days were imputed using the 
last-observation-carried forward technique. Further-
more, comparisons between the UC-II and G+C 
groups were made at each visit using analysis of 
variance, using the baseline visit as a covariate. SAS 
version 9.1 has been used to perform the statistical 
analysis. Probability values less than 0.05 were con-
sidered statistically significant for between-group 
comparisons.  
 
Results  
Baseline Statistics and Compliance of Trial Sub-
jects 
 Demographic and baseline characteristics of pa-
tients are summarized in Table 3. Overall, the patient 
profiles with respect to age, sex, height, weight, blood 
pressure, heart beat and target knee were similar be-
tween both treatment groups. Table 4 shows treat-
ment compliance of the trial patients. There were no 
significant interaction terms or between-group dif-
ferences for compliances. When compliances were 
compared at each visit, there were no overall be-
tween-group differences among the two treatment 
groups. 
 
 
Table 3. Demographic and baseline characteristics of the 
trial subjects 
  UC-II (N=26)  G + C (N=26) 
Age (years)  58.9 ± 9.79  58.7 ± 10.3 
Sex: male/female (%)  13/26 (50%)  17/26 (65%) 
Height (cm)  167.7 ± 9.90  167.0 ± 8.73 
Weight (kg)  84.3 ± 17.4  86.6 ± 21.0 
Systolic Blood Pressure 
(mm) 
128.2 ± 9.36  126.3 ± 12.5 
Diastolic Blood Pressure 
(mm) 
81.9 ± 7.43  79.7 ± 8.60 
Heart Rate (bpm)  68.2 ± 7.72  67.4 ± 8.47 
Target knee     
Left; n (%)  16 (61.5%)  13 (50%)   
Right; n (%)  10 (38.5%)  13 (50%) 
Where applicable, values are expressed as mean ± SD 
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Table 4. Treatment compliance as assessed during speci-
fied visits 
Treatment Group  Visit 
UC-II  G + C 
AM Capsule Compliance 
Visit 3  [25] 90.5 ± 19.2  [25] 93.6 ± 11.5 
Visit 4  [24] 93.2 ± 9.66  [26] 94.5 ± 11.8 
Visit 5  [23] 98.5 ± 5.15  [26] 93.3 ± 11.0 
PM Capsule Compliance 
Visit 3  [25] 88.1 ± 18.7  [25] 92.5 ± 12.5 
Visit 4  [24] 92.8 ± 8.97  [26] 91.6 ± 12.3 
Visit 5  [22] 95.3 ± 9.92  [26] 89.7 ± 12.6 
There were no significant interaction terms and between-group 
differences for compliances. When compliances were compared at 
each visit, there were no overall between-group differences among 
the five treatment groups. Values are expressed as [n] mean ± SD. 
 
WOMAC Score 
 The interaction between visit and treatment was 
significant in UC-II treated group for "pain walking 
on flat surface" (p=0.034), "difficulty walking on flat 
surface" (p=0.038) and "performing heavy domestic 
duties" (p=0.031) as compared to G+C treated group. 
There was evidence that UC-II treatment has a sig-
nificant effect for “ascending stairs” (p=0.013) as 
compared to G+C treatment. Additionally, when 
groups were compared at each visit, UC-II was sig-
nificantly better than G+C for “ascending stairs at 30 
days and 60 days” (p=0.019 & 0.040 respectively), “at 
night while in bed” (p=0.015) at 60 days and difficulty 
walking on flat surface at 90 days (p=0.035). There 
were no further statistically significant differences for 
any other individual WOMAC components or sum-
mary scores. Treatment with UC-II was most effective 
and reduced the WOMAC scores by 33% 
compared to 14% in (G+C)-treated groups after 90 
days. Within-group analysis indicated that treatment 
with UC-II for 90 days significantly (p<0.05) im-
proved WOMAC scores at all treatment time points 
measured. In contrast, subjects received G+C did not 
show any statistical significant change in WOMAC 
scores at Day 90 of treatment (Fig. 2). 
VAS Score 
 The interaction between visit and treatment was 
non-significant for all VAS components and summary 
scores. However there was evidence that UC-II 
treatment had a significant effect for “pain during 
climbing up and down stairs”, “night pain” and 
“resting pain” (p=0.035, 0.030 and 0.024 respectively). 
When groups were compared at each visit, UC-II was 
significantly better than G+C for “night pain” 
(p=0.040) and “resting pain” (p=0.020) at 60 days and 
“pain during climbing up and down stairs” (p=0.014) 
and “resting pain” at 90 days (p=0.034). There were no 
between-group differences for any of the VAS com-
ponents or summary scores.  Although  both  the 
treatments reduced the VAS score, UC-II was found to 
be more effective with a 40% decrease after 90 days of 
treatment compared to a 15% decrease in G+C treated 
groups.  
 Within-group analysis indicated that subjects on 
UC-II showed a significant reduction in total VAS 
scores at Day 60 and Day 90 as compared to baseline. 
However, subjects on G+C showed a significant re-
duction in total VAS scores at Day 30 and no signifi-
cant difference was observed at either Day 60 or Day 
90 as compared to baseline (Fig. 3).
 
Figure 2. Changes in WOMAC scores at Day 
90 from baseline. WOMAC scores from each 
treatment group were compared to baseline 
value at specified time points. Each bar presents 
mean ± SEM. *p<0.05, **p<0.005 indicate sig-
nificantly different from baseline. 
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Figure 3. Changes in VAS score at Day 90 from baseline. VAS scores from each treatment group were compared to 
baseline value at specified time points. Each bar presents mean ± SEM. **p<0.05 indicates significantly different from baseline. 
 
 
 
Lequesne Score 
  The Lequesne’s functional index was used to 
determine the effect of different treatments on pain 
during daily activities. The interaction between visit 
and treatment was non-significant for all Lequesne’s 
components and summary scores. Furthermore, there 
were no between-group differences for any of the 
Lequesne’s components or summary scores. However 
there was evidence that visit has a significant effect in 
UC-II treated group for “pain while up from sitting” 
and “maximum distance walked” (p=0.036 and 0.002 
respectively) as compared to G+C treated group.  
There was as a strong trend toward UC-II efficacy. 
UC-II treatment effectively reduced Lequesne’s func-
tional index score by 20.1% as compared to 5.9 % by 
G+C treatment.  
 Within-group  analysis  suggested that subjects 
on UC-II demonstrated a significant reduction in total 
Lequesne’s index of severity score from baseline to 
Day 90, whereas no significant difference from 
baseline was observed for subjects on G+C at any 
treatment time points evaluated (Fig. 4). 
 
 
 
Figure 4. Changes in Lequesne’s functional index at Day 
90 from baseline. Lequesne’s functional index from each 
treatment group was compared to baseline value at 
specified time points. Each bar presents mean ± SEM. 
*p<0.05 indicates significantly different from baseline. 
 
Adverse Events 
 Adverse effects that occurred during the 90-day 
trial period are summarized in Table 5. Overall, there 
were 58 adverse events noted in the subjects receiving 
G+C treatment, whereas, only 35 adverse events were 
observed in UC-II group. In terms of severity, 60% of 
mild and 38% of moderate adverse events were ex-
perienced by subjects on G+C in comparison to 43% 
and 54% by subjects on UC-II. In relationship to test 
product a higher number of subjects (23%) on G+C 
demonstrated adverse events possibly related to 
product as compared to 11.4% of subjects on UC-II. 
For UC-II the possible adverse events related to 
products were constipation and headaches (intermit-
tently). For G+C the possible adverse events related to 
products were bloating, stomach pain, rash, water 
retention (edema around eyes and scars), hives on 
face and chest, and headache. However, there was no 
significant difference in the occurrence of adverse 
effects between the two treatment groups. 
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Rescue Medication 
  A greater percentage of subjects used rescue 
medication while on G+C as compared to UC-II at 
every time point assessed. From baseline to Day 30 a 
total of 8 subjects (33.3%) on UC-II used rescue 
medication as compared to 23 subjects (88.5%) on 
G+C. From Day 30 to Day 60, 13 subjects (54.2%) on 
UC-II used rescue medication as compared to 21 sub-
jects (80.8%) on G+C. Fourteen subjects (63.6%) on 
UC-II used rescue medication as compared to 19 sub-
jects (79.2%) on G+C from Day 60 to Day 90.  
 
Table 5. Summary of analysis of adverse events in all subjects 
Treatment Group   
UC-II (n=26)  G + C (n=26) 
Severity (n) 
Mild  15 35 
Moderate  19 22 
Severe  1 1 
Relationship to Test Article (n) 
Not related  17 20 
Unlikely  14 30 
Possible  4 8 
Probable  0 0 
Most Probable  0  0 
Body System (n) 
Pain  10 17 
Gastrointestinal 5  15 
Musculoskeletal/Soft Tissue  7  5 
Neurology  0 2 
Pulmonary / Upper Respiratory  2  1 
Hemorrhage/Bleeding 2  1 
Blood/Bone Marrow  2  1 
Dermatology/Skin 2  3 
Allergy / Immunology  0  1 
Infection  1 3 
Lymphatics  0 1 
Hepatobilary / Pancreatic  0  0 
Renal / Genitoruinary  0  0 
Constitutional Symptoms  2  3 
Syndromes  1 1 
Auditory/Ear 0  1 
Ocular / Visual  0  1 
Metabolic / Laboratory  1  2 
Total Number of Adverse Events Experienced During Study (n)  35 58 
Total Number of Subjects Experiencing Adverse Events: n (%)  16/26 (61.5%)  20/26 (76.9%) 
 
Discussion  
OA is the most common form of arthritis, and it 
is often associated with significant disability and an 
impaired quality of life. Clinical and radiographic 
surveys have found that the prevalence of OA in-
creases with age from 1% in people <30 years to 10% 
in those <40 years to more than 50% in individuals 
>60 years of age (19). Although there are no curative 
therapies currently available for OA, individualized 
treatment programs are available to help relieve pain 
and stiffness, and to maintain and/or improve func-
tional status.  
  In the last few years, various nutritional sup-
plements including chondroitin, glucosamine, avo-
cado/soybean unsaponifiables and diacerein have 
emerged as new treatment options for osteoarthritis 
(20). In this study, the efficacy of UC-II was studied in 
patients identified with moderate to severe OA. The 
objective of this study was to determine the effect of 
UC-II on disease specific measures and blood meas-
ures of OA of the knee compared to G+C. It was hy-
pothesized that UC-II would reduce symptoms of OA 
of the knee to a greater extent than G+C.  
 A meta-analysis of 20 randomized control stud-
ies (2570 patients) comparing the effects of glucosa-
mine (glucosamine sulphate, GS or glucosamine HCl, 
GH) vs. placebo was done. Of these only eight studies 
met the required controlled conditions for adequate Int. J. Med. Sci. 2009, 6 
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allocation concealment and received a quality score of 
4 or higher (rated on the JADAD scale). These studies 
failed to show the benefit of glucosamine (GS or GH) 
for pain and WOMAC function. When all 20 studies 
were included in the meta-analysis, the results fa-
vored glucosamine with improvement in pain and 
functionality; however, the results were not uniformly 
positive and the parameters for WOMAC pain, daily 
function and stiffness did not reach statistical signifi-
cance. Combinations of glucosamine and chondroitin 
have been studied in the “GAIT” study. These authors 
reported that glucosamine HCl and chondroitin sul-
phate alone or in combination did not reduce pain 
significantly in patients with OA of the knee. How-
ever in a subgroup of patients with moderate to se-
vere knee pain the combination of compounds were 
found to be effective. Limitations to this study in-
cluded a high rate of response to placebo (60.1%) and 
the fact that 78% of the participants were in the mild 
pain subgroup (21).   
 Previous studies have shown that UC-II is effec-
tive in the treatment of RA (8-11), and preliminary 
human (12) and animal (13-15) trials have shown it to 
be effective in treating OA. In obese-arthritic dogs 
given 4 mg or 40 mg per day UC-II for 90 days, sig-
nificant declines in overall pain, pain during limb 
manipulation and lameness after physical exertion 
were noted (15). Greater improvement was observed 
with the 40 mg dose. No adverse effects or significant 
changes in serum chemistry (creatinine, blood urea 
nitrogen, alanine aminotransferase, and aspartate 
aminotransferase) were noted. Following UC-II 
withdrawal for a period of 30 days, all dogs experi-
enced a relapse of overall pain, exercise-associated 
lameness and pain upon limb manipulation. 
  In a recent investigation, efficacy of UC-II was 
evaluated in arthritic horses (22). In this study, groups 
of horses were orally administered with a daily dose 
of placebo, UC-II at 320, 480 or 640 mg, or a combina-
tion of glucosamine (5.4 g) and chondroitin (1.8 g) for 
150 days. Horses receiving placebo did not show any 
improvement in arthritic condition, while those re-
ceiving a daily dose of 320, 480 or 640 mg of UC-II 
exhibited significant reduction in arthritic pain. Al-
though G+C treated group showed significant reduc-
tion in pain compared to baseline values, the efficacy 
was less as compared to that observed with UC-II 
treatment. In fact, UC-II at 480 or 640 mg/day was 
found to be more effective than G+C in treatment of 
arthritic pain in horses. Clinical conditions (body 
weight, body temperature, respiration rate, and pulse 
rate), and liver (bilirubin, GGT, and ALP) and kidney 
(BUN and creatinine) functions were not affected by 
UC-II treatment, suggesting that UC-II is well toler-
ated and does not cause any adverse effects (22).  
 In a preliminary trial of subjects with OA, taking 
a single oral daily dose of 40 mg UC-II on an empty 
stomach prior to bedtime for 42 consecutive days, an 
average of 26% reduction of pain was noted in four of 
five subjects in the study. No side effects were associ-
ated with treatment (12). The precise biochemical 
mechanism involved in UC-II induced pharmacol-
ogical anti-arthritic effects in humans, dogs or horses 
is not clearly established. Type II collagen is the pri-
mary form of collagen contained in cartilage. Type II 
collagen extracts contain the amino acids found in the 
framework of human cartilage. In addition, these 
amino acids are required for the synthesis and repair 
of connective tissue throughout the body. These 
products reportedly aid in reducing the destruction of 
collagen within the body, may provide 
anti-inflammatory activity, and may improve joint 
flexibility (8-12).   
 The current study indicated that both treatments 
reduced the WOMAC scores, which measures the 
difficulty in physical function, stiffness and pain in 
the knee. However, treatment with UC-II was found 
to be more effective in reducing the WOMAC scores 
by 33% as compared to 14% in G+C treated groups 
after 90 days. Similar results were observed for VAS 
scores. Although both the treatments reduced the 
VAS score, UC-II was found to be more effective with 
40% decrease after 90 days of treatment as compared 
to 15.4% in G+C treated groups. The Lequesne’s 
functional index was used to determine the effect of 
different treatments on pain during daily activities. 
Treatment with UC-II reduced Lequesne’s functional 
index by 20.1% as compared to 5.9 % in G+C treated 
groups. Thus, UC-II supplementation showed im-
provement in daily activities suggesting an im-
provement in overall quality of life in the patients 
receiving UC-II. 
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